Importantly, following CD86 blockade, the frequency of proliferating (Ki67+) CD8+ T cells significantly increased in the tumor, while combined CD86 and PD-1 blockade increased this cell population in both the TdLN and tumor (Figure 7, B and D, and Supplemental Figure 8, B and C). This evidence concerns the gene CD86 and neoplasm.